{
  "first_published_at": "2013-09-09", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON314896", 
  "title": "Panitumumab: importance of establishing wildtype RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Cancer\"]}", 
  "_document_number": 55, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Panitumumab: importance of establishing wildtype RAS (KRAS and NRAS) status before treatment of metastatic colorectal cancer</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: September 2013</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>In the treatment of metastatic colorectal cancer, evidence of wildtype <em>RAS</em> status (at exons 2, 3, and 4 of <em>KRAS</em> and <em>NRAS</em>) is required before initiating treatment with panitumumab alone or in combination with other chemotherapy. Inferior progression-free survival and overall survival have been shown in patients with <em>RAS</em> mutations beyond <em>KRAS</em> exon 2 who received panitumumab combined with FOLFOX (oxaliplatin-containing) chemotherapy versus FOLFOX alone<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Panitumumab (Vectibix) is a treatment for adults with metastatic colorectal cancer. It is given alone or in combination with other chemotherapy.</p>\n\n<p>New safety information is available based on subset analysis of data from a randomised, multicentre phase III study (PRIME study 20050203) of panitumumab plus FOLFOX versus FOLFOX alone in patients with previously untreated wildtype <em>KRAS</em> metastatic colorectal cancer. FOLFOX is an oxaliplatin-containing chemotherapy regimen used for treatment of colorectal cancer.</p>\n\n<p>The outcomes of this retrospective analysis indicate inferior progression-free survival and overall survival in patients with <em>RAS</em> mutations beyond <em>KRAS</em> exon 2 who received panitumumab combined with FOLFOX chemotherapy versus FOLFOX alone.</p>\n\n<p>These findings are important and emphasise that panitumumab is contraindicated &#160;in combination with oxaliplatin-based chemotherapy in patients with mutant <em>RAS</em> (at exons 2, 3, or 4 of <em>KRAS</em> and <em>NRAS</em>), or in whom <em>RAS</em> status is unknown.</p>\n\n<p>It is also important that evidence of wildtype <em>RAS</em> status is established before initiation of treatment with panitumumab in all patients.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul type=\"disc\">\n<li>Evidence of wildtype <em>RAS</em> status (at exons 2, 3 and 4 of <em>KRAS</em> and <em>NRAS</em>) is required before initiating treatment with panitumumab</li>\n\n<li><em>RAS</em> mutation status should be determined by an experienced laboratory using a validated test method</li>\n\n<li>Panitumumab is contraindicated in combination with oxaliplatin-containing chemotherapy (eg, FOLFOX) in all patients with mutant or unknown <em>RAS</em> status</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON309643\" target=\"_blank\">Letter sent to healthcare professionals, August 2013</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update September 2013 volume 7, issue 2: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Panitumumab (Vectibix) is a treatment for adults with metastatic colorectal cancer. It is given alone or in combination with other chemotherapy.</p>\n\n<p>New safety information is available based on subset analysis of data from a randomised, multicentre phase III study (PRIME study 20050203) of panitumumab plus FOLFOX versus FOLFOX alone in patients with previously untreated wildtype <em>KRAS</em> metastatic colorectal cancer. FOLFOX is an oxaliplatin-containing chemotherapy regimen used for treatment of colorectal cancer.</p>\n\n<p>The outcomes of this retrospective analysis indicate inferior progression-free survival and overall survival in patients with <em>RAS</em> mutations beyond <em>KRAS</em> exon 2 who received panitumumab combined with FOLFOX chemotherapy versus FOLFOX alone.</p>\n\n<p>These findings are important and emphasise that panitumumab is contraindicated &#160;in combination with oxaliplatin-based chemotherapy in patients with mutant <em>RAS</em> (at exons 2, 3, or 4 of <em>KRAS</em> and <em>NRAS</em>), or in whom <em>RAS</em> status is unknown.</p>\n\n<p>It is also important that evidence of wildtype <em>RAS</em> status is established before initiation of treatment with panitumumab in all patients.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul type=\"disc\">\n<li>Evidence of wildtype <em>RAS</em> status (at exons 2, 3 and 4 of <em>KRAS</em> and <em>NRAS</em>) is required before initiating treatment with panitumumab</li>\n\n<li><em>RAS</em> mutation status should be determined by an experienced laboratory using a validated test method</li>\n\n<li>Panitumumab is contraindicated in combination with oxaliplatin-containing chemotherapy (eg, FOLFOX) in all patients with mutant or unknown <em>RAS</em> status</li>\n</ul>\n</div>\n\n<p><strong>Further information:</strong></p>\n\n<p><a href=\"http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON309643\" target=\"_blank\">Letter sent to healthcare professionals, August 2013</a></p>\n\n<p>&#160;</p>\n\n<p><em>Article citation: Drug Safety Update September 2013 volume 7, issue 2: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2013-09-01", 
  "date_last_modified": "2013-09-09", 
  "_assets": [], 
  "_item_id": 55, 
  "summary": "In the treatment of metastatic colorectal cancer, evidence of wildtype RAS status (at exons 2, 3, and 4 of KRAS and NRAS) is required before initiating treatment with panitumumab alone or in combination with other chemotherapy. Inferior progression-free survival and overall survival have been shown in patients with RAS mutations beyond KRAS exon 2 who received panitumumab combined with FOLFOX (oxaliplatin-containing) chemotherapy versus FOLFOX alone", 
  "body": "Article date: September 2013\n\nPanitumumab (Vectibix) is a treatment for adults with metastatic colorectal cancer. It is given alone or in combination with other chemotherapy.\n\nNew safety information is available based on subset analysis of data from a randomised, multicentre phase III study (PRIME study 20050203) of panitumumab plus FOLFOX versus FOLFOX alone in patients with previously untreated wildtype KRAS metastatic colorectal cancer. FOLFOX is an oxaliplatin-containing chemotherapy regimen used for treatment of colorectal cancer.\n\nThe outcomes of this retrospective analysis indicate inferior progression-free survival and overall survival in patients with RAS mutations beyond KRAS exon 2 who received panitumumab combined with FOLFOX chemotherapy versus FOLFOX alone.\n\nThese findings are important and emphasise that panitumumab is contraindicated  in combination with oxaliplatin-based chemotherapy in patients with mutant RAS (at exons 2, 3, or 4 of KRAS and NRAS), or in whom RAS status is unknown.\n\nIt is also important that evidence of wildtype RAS status is established before initiation of treatment with panitumumab in all patients.\n\nAdvice for healthcare professionals:  \n  \n  * Evidence of wildtype RAS status (at exons 2, 3 and 4 of KRAS and NRAS) is required before initiating treatment with panitumumab  \n  * RAS mutation status should be determined by an experienced laboratory using a validated test method  \n  * Panitumumab is contraindicated in combination with oxaliplatin-containing chemotherapy (eg, FOLFOX) in all patients with mutant or unknown RAS status  \n  \nFurther information:\n\n[Letter sent to healthcare professionals, August 2013](http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON309643)\n\n \n\nArticle citation: Drug Safety Update September 2013 volume 7, issue 2: A2.\n"
}